Hopp’s bitter harvest as Wilex wanes and Sygnis sings swansong
This article was originally published in Scrip
Executive Summary
While Dietmar Hopp clearly had a Midas touch when it came to investing in technology, the billionaire SAP founder has not had the same luck in the life sciences. Strategic changes will have to be on the cards at Wilex and Sygnis Pharma, two of dievini Hopp BioTech's leading portfolio companies.